JPS5248687A - Production of pyroro *3*44b* pyrazine derivative - Google Patents

Production of pyroro *3*44b* pyrazine derivative

Info

Publication number
JPS5248687A
JPS5248687A JP51106831A JP10683176A JPS5248687A JP S5248687 A JPS5248687 A JP S5248687A JP 51106831 A JP51106831 A JP 51106831A JP 10683176 A JP10683176 A JP 10683176A JP S5248687 A JPS5248687 A JP S5248687A
Authority
JP
Japan
Prior art keywords
pyroro
production
pyrazine derivative
pyrazine
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP51106831A
Other languages
English (en)
Other versions
JPS5231358B2 (ja
Inventor
Kotoreru Kuroodo
Jiyanmaaru Kuroodo
Noomu Mutsuse Maieru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc SA
Original Assignee
Rhone Poulenc SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7200505A external-priority patent/FR2166314A1/fr
Priority claimed from FR7239731A external-priority patent/FR2205318A2/fr
Application filed by Rhone Poulenc SA filed Critical Rhone Poulenc SA
Publication of JPS5248687A publication Critical patent/JPS5248687A/ja
Publication of JPS5231358B2 publication Critical patent/JPS5231358B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP51106831A 1972-01-07 1976-09-08 Production of pyroro *3*44b* pyrazine derivative Granted JPS5248687A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7200505A FR2166314A1 (en) 1972-01-07 1972-01-07 6-substd 5-(4-methyl 1-piperazinyl)carbonyloxy 7-oxo - 5,6-dihydro-pyrrolo (3,4-b)pyrazines - tranquillizers and anticonvuls
FR7239731A FR2205318A2 (en) 1972-11-09 1972-11-09 6-substd 5-(4-methyl 1-piperazinyl)carbonyloxy 7-oxo - 5,6-dihydro-pyrrolo (3,4-b)pyrazines - tranquillizers and anticonvuls

Publications (2)

Publication Number Publication Date
JPS5248687A true JPS5248687A (en) 1977-04-18
JPS5231358B2 JPS5231358B2 (ja) 1977-08-13

Family

ID=26216824

Family Applications (3)

Application Number Title Priority Date Filing Date
JP48000069A Expired JPS523952B2 (ja) 1972-01-07 1973-01-05
JP51106832A Granted JPS5248688A (en) 1972-01-07 1976-09-08 Production of pyroro *3*44b* pyrazine derivative
JP51106831A Granted JPS5248687A (en) 1972-01-07 1976-09-08 Production of pyroro *3*44b* pyrazine derivative

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP48000069A Expired JPS523952B2 (ja) 1972-01-07 1973-01-05
JP51106832A Granted JPS5248688A (en) 1972-01-07 1976-09-08 Production of pyroro *3*44b* pyrazine derivative

Country Status (22)

Country Link
US (1) US3862149A (ja)
JP (3) JPS523952B2 (ja)
AR (1) AR195097A1 (ja)
AT (1) AT323181B (ja)
AU (1) AU466586B2 (ja)
BE (1) BE793730A (ja)
CA (1) CA991183A (ja)
CY (1) CY915A (ja)
DD (1) DD102698A5 (ja)
DE (1) DE2300491C3 (ja)
DK (1) DK139359B (ja)
FI (1) FI54124C (ja)
GB (1) GB1358680A (ja)
HK (1) HK60077A (ja)
HU (1) HU164821B (ja)
IE (1) IE37056B1 (ja)
IL (1) IL41232A (ja)
LU (1) LU66800A1 (ja)
NL (1) NL7217852A (ja)
NO (1) NO136843C (ja)
OA (1) OA04285A (ja)
SE (1) SE398503B (ja)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR208414A1 (es) * 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
FR2322601A1 (fr) * 1975-09-04 1977-04-01 Rhone Poulenc Ind Nouveaux derives de l'isoindoline, leur preparation et les compositions qui les contiennent
ATE39483T1 (de) * 1982-04-02 1989-01-15 Takeda Chemical Industries Ltd Kondensierte pyrrolinon-derivate, und ihre herstellung.
JPS6169773A (ja) * 1984-09-14 1986-04-10 Takeda Chem Ind Ltd イソインドリノン誘導体
JPS6297400U (ja) * 1985-12-09 1987-06-20
FR2607504B1 (fr) * 1986-12-02 1989-01-27 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2671800B1 (fr) * 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
US5786357A (en) * 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
WO1993010787A1 (en) * 1991-12-02 1993-06-10 Sepracor, Inc. Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
AU3275993A (en) * 1991-12-02 1993-06-28 Sepracor, Inc. Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone
US6348485B1 (en) 1998-06-09 2002-02-19 Takeda Chemical Industries, Ltd. Method for treating or preventing sleep disorders
US6339086B1 (en) 1999-05-14 2002-01-15 Swpracor, Inc. Methods of making and using N-desmethylzopiclone
ES2203319B1 (es) * 2002-04-03 2005-03-01 Universidad De Oviedo Nuevos carbonatos opticamente activos como intermedios en la sintesis de (+)-zopiclona.
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
EP1904046A4 (en) * 2005-07-06 2008-10-01 Sepracor Inc COMBINATIONS OF ESZOPICLON AND O-DESMETHYLVENLAFAXINE AND METHOD FOR THE TREATMENT OF MENOPAUSE AND HUMOR FLUCTUATIONS; ANXIETY AND COGNITIVE INTERFERENCE
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7476737B2 (en) * 2005-09-05 2009-01-13 Dr. Reddy's Laboratories Limited Eszopiclone process
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1984371A1 (en) * 2006-02-03 2008-10-29 Synthon B.V. Zopiclone resolution using l-tartaric acid
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20080027223A1 (en) * 2006-03-23 2008-01-31 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
JP2008543953A (ja) * 2006-04-20 2008-12-04 テバ ファーマシューティカル インダストリーズ リミティド エスゾピクロン結晶形態ａ、実質的に純粋なエスゾピクロン及び光学的に豊富なエスゾピクロンを調製するための方法
CN101058581B (zh) * 2006-04-21 2011-06-08 天津天士力集团有限公司 右佐匹克隆中间体6-(5-氯-2-吡啶基)-5,7-二氧代-6,7-二氢-5H-吡咯并[3,4-b]吡嗪的制备方法
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP1904499A1 (en) * 2006-06-26 2008-04-02 Teva Pharmaceutical Industries Ltd Process for the preparation of zopiclone
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US7786304B2 (en) * 2006-11-06 2010-08-31 Centaur Pharmaceutical Pvt. Ltd. Process for the preparation of eszopiclone
TW200846340A (en) * 2007-01-31 2008-12-01 Teva Pharma Methods for preparing eszopiclone
US20080305171A1 (en) * 2007-06-07 2008-12-11 Kristin Anne Arnold Pyrrolopyrazine, formulations, methods of manufacture, and methods of use there
TW200918534A (en) * 2007-06-25 2009-05-01 Teva Pharma Racemization process of R-zopiclone
EP2020403A1 (en) 2007-08-02 2009-02-04 Esteve Quimica, S.A. Process for the resolution of zopiclone and intermediate compounds
US20090198058A1 (en) * 2007-08-06 2009-08-06 Dhananjay Govind Sathe Process for Preparation of Dextrorotatory Isomer of 6-(5- chloro-pyrid-2-yl)-5-[(4-methyl -1-piperazinyl) carbonyloxy] -7-oxo-6,7-dihydro-5H-pyrrolo [3,4-b] pyrazine (Eszopiclone)
AU2008346110A1 (en) * 2007-12-11 2009-07-16 Cipla Ltd. Crystalline polymorphic forms of zopiclone, processes for their preparation and their pharmaceutical compositions
CN100467471C (zh) * 2007-12-19 2009-03-11 齐鲁天和惠世制药有限公司 佐匹克隆的制备方法
US8198277B2 (en) * 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
WO2009085972A1 (en) * 2007-12-19 2009-07-09 Sepracor Inc. Maleate, besylate, and l-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine
US20110053945A1 (en) * 2007-12-19 2011-03-03 Sepracor Inc. Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihy-dro-5h-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8212036B2 (en) * 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
AU2010208240A1 (en) 2009-01-30 2011-09-22 Sunovion Pharmaceuticals Inc Coated tablets of 6-(5-chloro-2-pyridyl) -5-[ (4-methyl-1-piperazinyl) carbonyloxy]-7-oxo-6, 7-dihydro-5H-pyrrol o [3,4-b] pyrazine and methods for measuring effectiveness of coating
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN105399745A (zh) * 2015-12-17 2016-03-16 天津华津制药有限公司 一种吡嗪并羟基吡咯烷酮类化合物的制备方法
EP3468545B1 (en) 2016-06-08 2026-08-05 President and Fellows of Harvard College Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome
CN106220630B (zh) * 2016-07-23 2019-12-10 迪嘉药业集团有限公司 一种n-取代吡咯并[3,4-b]吡嗪-5,7(6h)-二酮的制备方法
WO2019226808A1 (en) 2018-05-22 2019-11-28 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
EP3801512A4 (en) 2018-05-29 2022-01-19 President and Fellows of Harvard College COMPOSITIONS AND METHODS TO REDUCE TACTILE DYSFUNCTION, ANXIETY AND SOCIAL DISABILITIES
US12077512B2 (en) 2019-03-25 2024-09-03 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
CN114437027A (zh) * 2021-12-22 2022-05-06 深圳市祥根生物医药有限公司 一种佐匹克隆n-氧化杂质的制备方法

Also Published As

Publication number Publication date
CY915A (en) 1977-12-23
DE2300491B2 (de) 1977-09-08
LU66800A1 (ja) 1973-07-18
NL7217852A (ja) 1973-07-10
JPS5248688A (en) 1977-04-18
AR195097A1 (es) 1973-09-10
DE2300491C3 (de) 1978-05-18
AT323181B (de) 1975-06-25
JPS5231358B2 (ja) 1977-08-13
SE398503B (sv) 1977-12-27
AU466586B2 (en) 1975-10-30
DK139359C (ja) 1979-07-09
IL41232A0 (en) 1973-03-30
BE793730A (fr) 1973-07-05
JPS4876892A (ja) 1973-10-16
AU5075473A (en) 1974-07-04
DK139359B (da) 1979-02-05
OA04285A (fr) 1979-12-31
IE37056L (en) 1973-07-07
JPS523952B2 (ja) 1977-01-31
IL41232A (en) 1975-12-31
DE2300491A1 (de) 1973-07-19
NO136843C (no) 1977-11-16
NO136843B (no) 1977-08-08
US3862149A (en) 1975-01-21
HU164821B (ja) 1974-04-11
DD102698A5 (ja) 1973-12-20
GB1358680A (en) 1974-07-03
JPS535315B2 (ja) 1978-02-25
FI54124B (fi) 1978-06-30
IE37056B1 (en) 1977-04-27
HK60077A (en) 1977-12-09
CA991183A (fr) 1976-06-15
FI54124C (fi) 1978-10-10

Similar Documents

Publication Publication Date Title
JPS5248688A (en) Production of pyroro *3*44b* pyrazine derivative
JPS5543081A (en) Manufacture of 2*1*33benzothiadiazole derivative
ZA737580B (en) Production of fibrils
CA1013092A (en) Production of polyamides
IL43643A0 (en) Production of ypsilon-globulin
JPS5297958A (en) Production of intermediate of 155substituteddomegaa pentanoprostaglandine
JPS55153766A (en) Manufacture of 99substituted 33aminocarbazole derivative
JPS5318550A (en) Production of 22aminoo *1*2*3*44tetrahydronaphthalene* derivatives
JPS5699460A (en) Manufacture of 2*66diaminoodihydropyridines
CA1010064A (en) Production of dialkylphosphines
AU471172B2 (en) Production of tetrachlorophthalonitriles
IL41542A0 (en) The production of substituted pyridines
JPS5522675A (en) Manufacture of pyrrolo*3*44b*pyridine derivative
CA970978A (en) Production of iron
PH12351A (en) Novel derivatives of 6 alpha-methyl-prednisolone
JPS5217466A (en) Production of 55 benzoylindolinee22one
JPS5257192A (en) Production of nitroimidazolyll triazoroopyridazine
IL41374A0 (en) The production of benzocyclohepta-thiophene derivatives
GB1394843A (en) Production of synthetic polynucleotides
JPS54138578A (en) Manufacture of 33oxyy2*33dihydroo1*44benzoxazine derivative
JPS5430189A (en) Production of 2*44diaminoo 55benzylpyrimidine derivative
CA906494A (en) Production of n-aryl-cyclicimide compounds
ZA745852B (en) Production of 4-oxa-5-hydroxypolycycloalkenones-(3)
AU459220B2 (en) Production of electrets
CA1000743A (en) Production of hydroxyalkylcycloalkanols